e-learning
resources
Berlin 2008
Tuesday, 07.10.2008
Medical treatment of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inhalation of vasoactive intestinal peptide in pulmonary hypertension
H. Leuchte, C. Baezner, R. Baumgartner, C. Neurohr, D. Bevec, G. Bacher, J. Behr (Munich, Germany; Basel, Switzerland)
Source:
Annual Congress 2008 - Medical treatment of pulmonary hypertension
Session:
Medical treatment of pulmonary hypertension
Session type:
Oral Presentation
Number:
3177
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Leuchte, C. Baezner, R. Baumgartner, C. Neurohr, D. Bevec, G. Bacher, J. Behr (Munich, Germany; Basel, Switzerland). Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008; 32: Suppl. 52, 3177
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Inhalation of vasoactive intestinal peptide in pulmonary hypertension
Source: Eur Respir J 2008; 32: 1289-1294
Year: 2008
Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets
Source: Eur Respir J 2006; 28: Suppl. 50, 659s
Year: 2006
Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis
Source: Eur Respir J 2004; 24: 958-963
Year: 2004
N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2005; 25: 509-513
Year: 2005
Vasoactive intestinal peptide (VIP) markedly attenuates pulmonary hypertension in fawn-hooded rats
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Augmentation of the effects of vasoactive intestinal peptide aerosol on pulmonary hypertension via co-application of a neutral endopeptidase 24.11 inhibitor
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Inhaled vasoactive intestinal peptide exerts immune-regulatory effects in patients with sarcoidosis
Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases
Year: 2009
Acute vasodilator response in different forms of pre-capillary pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Distribution of vasoactive intestinal peptide( VIP)- and substance P (SP)- containing innervation in bronchi of patients with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 128s
Year: 2004
Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2006 - Cellular mechanisms of airway disease
Year: 2006
Association of haemodynamic parameters with circulating natriuretic peptides in precapillary pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load
Year: 2015
Effects of different pacing modes on vasoactive intestinal peptide levels in pacemaker patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 58s
Year: 2001
Effects of inhaled salbutamol in primary pulmonary hypertension
Source: Eur Respir J 2002; 20: 524-528
Year: 2002
Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 111s
Year: 2004
Vasoactive and growth factors in pulmonary emphysema
Source: Annual Congress 2010 - Pulmonary vascular involvement in COPD
Year: 2010
Vasoactive intestinal peptide-receptor regulation in monocytes derived from COPD patients
Source: Annual Congress 2007 - Cell biology of asthma and COPD
Year: 2007
Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 24s
Year: 2002
Brief adrenomedullin inhalation leads to sustained reduction of pulmonary artery pressure
Source: Eur Respir J 2004; 24 : 615-623
Year: 2004
Inhaled vasoactive intestinal peptide (VIP) improves pulmonary gas exchange in acute respiratory distress syndrome (ARDS) - a case report
Source: Eur Respir J 2003; 22: Suppl. 45, 70s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept